Patient Success Stories : Many clients have achieved remarkable results
Signing up for Ivy Rx happens entirely online
OTHERS Recent investigations have elucidated a multifaceted spectrum of adverse effects linked to GLP-1 RAs (Table 1), necessitating meticulous interpretation based on the various methodological designs employed, including RCTs and retrospective analyses
Reading Published Dose Ranges Correctly Retatrutides Phase 3 TRIUMPH-1 trial, with topline results reported by Eli Lilly in May 2026, evaluated three target doses 4mg, 9mg, and 12mg weekly with all arms starting at 2mg and escalating in steps every four weeks (2mg 4mg 6mg 9mg 12mg, depending on target arm) rather than starting at the target dose directly
The safety risks of obtaining GLP-1 medications from unverified vendors far outweigh any cost savings
But the FDA declared the shortages over in February based on data from Eli Lilly and Novo Nordisk showing they could meet demand, giving compounders a few months to wind down production
